<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334734</url>
  </required_header>
  <id_info>
    <org_study_id>PBTZ169-A15-C2A-1</org_study_id>
    <nct_id>NCT03334734</nct_id>
  </id_info>
  <brief_title>Phase 2a Study of PBTZ169</brief_title>
  <official_title>Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nearmedic Plus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OCT LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nearmedic Plus LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open, randomized study with active control (isoniazid) to evaluate the early
      antibacterial activity, safety and pharmacokinetics of the drug PBTZ169 (capsules 80 mg) when
      used in patients with first-diagnosed tuberculosis of the respiratory system with bacterial
      excretion and saved bacterial susceptibility to isoniazid and rifampicin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2a study is aimed to evaluate the early bactericidal activity of a new
      anti-tuberculosis drug PBTZ169 (capsules 80 mg), and its results will allow preliminary
      evaluate antimycobacterial properties of PBTZ169 and confirm a potentially more effective
      dose for subsequent studies. This study is an open, randomized comparative efficacy (on the
      parameter of early bactericidal activity), safety and pharmacokinetics study of PBTZ169 in
      patients with first-diagnosed lung tuberculosis and preserved sensitivity to base
      antimycobacterial drugs: rifampicin and isoniazid.

      Within the framework of the study, it is planned to use the studied drugs (PBTZ169 and
      isoniazid) as monotherapy within 14 days. Isoniazid is used as a &quot;positive control&quot;, that is,
      in order to determine whether the method of assessing efficacy on the parameter of early
      bactericidal activity is working.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very slow enrollment
  </why_stopped>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Actual">February 22, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Bactericidal Activity (0-14)</measure>
    <time_frame>14 days after the onset of monotherapy</time_frame>
    <description>Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): agar inoculation, the mean of two measurements at the Visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early Bactericidal Activity (0-14)</measure>
    <time_frame>14 days after the onset of monotherapy</time_frame>
    <description>Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): PCR, the mean of two measurements at the Visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (0-2)</measure>
    <time_frame>2 days after the onset of monotherapy</time_frame>
    <description>EBA (0-2): agar inoculation, the mean of two measurements at the Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (0-7)</measure>
    <time_frame>7 days after the onset of monotherapy</time_frame>
    <description>EBA (0-7): agar inoculation, the mean of two measurements at the Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (0-2)</measure>
    <time_frame>2 days after the onset of monotherapy</time_frame>
    <description>EBA (0-2): PCR, the mean of two measurements at the Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Bactericidal Activity (0-7)</measure>
    <time_frame>7 days after the onset of monotherapy</time_frame>
    <description>EBA (0-7): PCR, the mean of two measurements at the Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Сmax) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Peak plasma concentration (Сmax) of PBTZ169 for multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Plasma Concentration (Сmin) of PBTZ169</measure>
    <time_frame>for single dosing , Day 1 (24 h after 1st dose of PBTZ169)</time_frame>
    <description>Minimal plasma concentration (Сmin) of PBTZ169: concentration measurement following single dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Concentration (Ctrough) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Residual concentration (Ctrough) of PBTZ169, measured 24 hours after the first dose administration, prior to the last dose, and 24 hours after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Plasma Concentration (Сmin) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Minimal plasma concentration (Сmin) of PBTZ169: multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) of PBTZ169</measure>
    <time_frame>for single dosing , Day 1 (24 h after 1st dose of PBTZ169)</time_frame>
    <description>Time to reach maximum concentration (Tmax) of PBTZ169 after single oral administration in different doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Time to reach maximum concentration (Tmax) of PBTZ169 after multiple oral administration in different doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)</measure>
    <time_frame>Up to 24 hours after the first drug administration</time_frame>
    <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Сmax) of PBTZ169</measure>
    <time_frame>for single dosing , Day 1 (24 h after 1st dose of PBTZ169)</time_frame>
    <description>Peak plasma concentration (Сmax) of PBTZ169: concentration measurement following single dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)</measure>
    <time_frame>Up to 24 hours after the last drug administration</time_frame>
    <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours] for the last dosing (Day 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (0-t)</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-last concentration above lower limit of quantification (LLoQ)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-∞) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Area under the plasma concentration versus time curve in frames [0-∞]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratios for the PK Parameters AUC(0 -24)</measure>
    <time_frame>24 hours after the first and the last drug administration</time_frame>
    <description>Accumulation ratios for the PK parameter AUC(0 -24): AUC(0- 24,ss)/AUC(0 -24), Day 1, on the original scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration (Css,av) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Average steady-state concentration in the dosing interval following multiple dosing was evaluated as the ratio AUC0 24/τ (τ = the dosing interval)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuations (%) in the Dosing Interval</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Fluctuations (%) in the dosing interval after multiple dosing ((Cmax - Cmin) × 100%/Css,av)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total (Plasma) Clearance (Clt) of PBTZ169</measure>
    <time_frame>24 hours after the first drug administration</time_frame>
    <description>Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total (Plasma) Clearance (Clt) of PBTZ169</measure>
    <time_frame>24 hours after the last drug administration</time_frame>
    <description>Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) of PBTZ169</measure>
    <time_frame>Up to 72 hours after the last drug administration</time_frame>
    <description>Distribution volume Vd for a dosing interval of 72 hours after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half-life Time (T1/2) of PBTZ169</measure>
    <time_frame>24 hours after the fist drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half-life Time (T1/2) of PBTZ169</measure>
    <time_frame>24 hours after the last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Constant (Kel) of PBTZ169</measure>
    <time_frame>24 hours after the first drug administration</time_frame>
    <description>Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Constant (Kel) of PBTZ169</measure>
    <time_frame>72 hours after the last drug administration</time_frame>
    <description>Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>PBTZ169, 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules 80 mg of PBTZ169 once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBTZ169, 320 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules 80 mg of PBTZ169 once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBTZ169, 640 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 capsules 80 mg of PBTZ169 once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoniazid, 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets 300 mg of Isoniazid once a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBTZ169</intervention_name>
    <description>Once a day for 14 days</description>
    <arm_group_label>PBTZ169, 160 mg</arm_group_label>
    <arm_group_label>PBTZ169, 320 mg</arm_group_label>
    <arm_group_label>PBTZ169, 640 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Once a day for 14 days</description>
    <arm_group_label>Isoniazid, 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent received from a volunteer

          -  Men and women aged 18 to 65 years, inclusive

          -  The first-diagnosed active pulmonary tuberculosis, confirmed by characteristic
             radiographic changes (infiltration, dissemination, destruction) during radiography or
             computed tomography of chest organs, without damage to other organs or with the defeat
             of one or more of the following organs: larynx, trachea, bronchi, lymph nodes

          -  The amount of sputum given by the patient is sufficient for carrying out the analyzes
             provided for by the protocol, but not less than 4-5 ml at the screening

          -  The presence of acid-fast mycobacteria in the sputum according to the results of
             microscopy of smears (1+ and more using the method of microscopy with luminescent dye
             staining according to the Order of the Ministry of Health of the Russian Federation of
             March 21, 2003 No. 109, the last edition) and the detection of the DNA of mycobacteria
             of tuberculosis by the results of molecular genetic methods of diagnosis

          -  Body weight not less than 51 kg

          -  Body mass index of 18.5-25 kg/m2

          -  Ability, according to investigators opinion, to comply with all requirements of the
             protocol

          -  Agreement to use double contraception method during the study participation and for 3
             months after the test drug administration - combination of male condom with not less
             than one of the following methods:

               -  female partner using hormonal contraception;

               -  using aerosols, creams, suppositories and other agents containing spermicides;

               -  female partner using intrauterine device

        Exclusion Criteria:

          -  Extrapulmonary localization of tuberculosis

          -  Presence of resistance to rifampicin and / or isoniazid in the study of sputum samples
             using molecular genetic methods

          -  Admission of any anti-tuberculosis drugs from the moment of diagnosis of tuberculosis
             to the moment of inclusion in the study

          -  The presence of absolute indications for surgical treatment of tuberculosis at the
             time of screening

          -  Positive tests for serological markers of syphilis or HIV infection during screening;
             active hepatitis or decompensated hepatic cirrhosis

          -  Aggravated allergic history, including presence of at least one episode of drug
             allergy

          -  The values of renal and / or hepatic parameters according to laboratory analyzes
             (taking into account the range of normal laboratory values):

               -  Aspartate aminotransferase (AST) level &gt; 2.0 x upper limit of the norm

               -  Alanine aminotransferase (ALT) level &gt; 2.0 x upper limit of norm

               -  General bilirubin level &gt; 1.5 x upper limit of norm

               -  Creatinine level &gt; 1.5 x upper limit of norm

          -  Individual drug components intolerance

          -  Presence in the anamnesis of malignant neoplasms, except for basal cell skin cancer

          -  The presence of severe chronic somatic diseases in the stage of decompensation,
             including diseases of the cardiovascular, bronchopulmonary, neuroendocrine system,
             ear, nose and throat (ENT) organs, the gastrointestinal tract, liver, kidneys, blood,
             skin, or any other somatic or mental diseases that, according to the researcher,
             prevent the patient from entering the study

          -  Gastrointestinal surgeries (except for appendectomy performed not less than 1 year
             before screening)

          -  Mental illness that may interfere with the patient's compliance with the protocol

          -  Diabetes mellitus

          -  Acute viral and bacterial infections at the time of enrollment or within 2 weeks
             before enrollment

          -  Alcoholism (except in cases when the patient is able, in the opinion of the
             researcher, to refrain from taking alcohol during the period of participation in the
             study), drug addiction, abuse of medicines

          -  Positive tests for narcotic and psychotropic agents

          -  Regular admission or use (including externally) of any hormonal medicines lasting more
             than 1 week less than 30 days before screening (with the exception of oral hormonal
             contraceptives and intrauterine spirals containing hormones)

          -  Use of cytostatic drugs less than 30 days before screening

          -  Multiple admission of drugs with the described in the instructions for medical use
             adverse events related to nervous system, hemodynamic and hepatic functions with
             frequencies &quot;very frequent&quot; (≥10%) and &quot;often&quot; (≥1% and &lt;10%) less than 21 days before
             screening

          -  Pregnancy or lactation period

          -  Planned conception or sperm donation during the study after the test drug
             administration or during 3 months after the last date of drug administration

          -  Participation in other clinical studies of drugs within less than 3 months before the
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <results_first_submitted>February 20, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>PBTZ169</keyword>
  <keyword>antimycobacterial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03334734/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PBTZ169, 160 mg</title>
          <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="P2">
          <title>PBTZ169, 320 mg</title>
          <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="P3">
          <title>PBTZ169, 640 mg</title>
          <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Isoniazid, 600 mg</title>
          <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PBTZ169, 160 mg</title>
          <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="B2">
          <title>PBTZ169, 320 mg</title>
          <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="B3">
          <title>PBTZ169, 640 mg</title>
          <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Isoniazid, 600 mg</title>
          <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="13.0"/>
                    <measurement group_id="B2" value="48.8" spread="10.7"/>
                    <measurement group_id="B3" value="43.7" spread="14.8"/>
                    <measurement group_id="B4" value="41.0" spread="0"/>
                    <measurement group_id="B5" value="46.1" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Early Bactericidal Activity (0-14)</title>
        <description>Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): agar inoculation, the mean of two measurements at the Visit</description>
        <time_frame>14 days after the onset of monotherapy</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid, 600 mg</title>
            <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (0-14)</title>
          <description>Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): agar inoculation, the mean of two measurements at the Visit</description>
          <population>FAS</population>
          <units>CFU per 1 mL of sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.085"/>
                    <measurement group_id="O2" value="0.015" spread="0.025"/>
                    <measurement group_id="O3" value="0.071" spread="0.126"/>
                    <measurement group_id="O4" value="0.237" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Early Bactericidal Activity (0-14)</title>
        <description>Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): PCR, the mean of two measurements at the Visit</description>
        <time_frame>14 days after the onset of monotherapy</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid, 600 mg</title>
            <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (0-14)</title>
          <description>Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): PCR, the mean of two measurements at the Visit</description>
          <population>FAS</population>
          <units>cell count per 1 mL of sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="0.081"/>
                    <measurement group_id="O2" value="-0.014" spread="0.048"/>
                    <measurement group_id="O3" value="0.097" spread="0.136"/>
                    <measurement group_id="O4" value="-0.099" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (0-2)</title>
        <description>EBA (0-2): agar inoculation, the mean of two measurements at the Visit</description>
        <time_frame>2 days after the onset of monotherapy</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid, 600 mg</title>
            <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (0-2)</title>
          <description>EBA (0-2): agar inoculation, the mean of two measurements at the Visit</description>
          <population>FAS</population>
          <units>CFU per 1 mL of sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.496" spread="0.615"/>
                    <measurement group_id="O2" value="0.124" spread="0.095"/>
                    <measurement group_id="O3" value="-0.003" spread="0.452"/>
                    <measurement group_id="O4" value="-0.243" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (0-7)</title>
        <description>EBA (0-7): agar inoculation, the mean of two measurements at the Visit</description>
        <time_frame>7 days after the onset of monotherapy</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid, 600 mg</title>
            <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (0-7)</title>
          <description>EBA (0-7): agar inoculation, the mean of two measurements at the Visit</description>
          <population>FAS</population>
          <units>CFU per 1 mL of sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.078" spread="0.136"/>
                    <measurement group_id="O2" value="0.026" spread="0.069"/>
                    <measurement group_id="O3" value="0.064" spread="0.102"/>
                    <measurement group_id="O4" value="0.090" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (0-2)</title>
        <description>EBA (0-2): PCR, the mean of two measurements at the Visit</description>
        <time_frame>2 days after the onset of monotherapy</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid, 600 mg</title>
            <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (0-2)</title>
          <description>EBA (0-2): PCR, the mean of two measurements at the Visit</description>
          <population>FAS</population>
          <units>cell count per 1 mL of sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.110" spread="0.872"/>
                    <measurement group_id="O2" value="0.007" spread="0.084"/>
                    <measurement group_id="O3" value="0.085" spread="0.397"/>
                    <measurement group_id="O4" value="0.627" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Bactericidal Activity (0-7)</title>
        <description>EBA (0-7): PCR, the mean of two measurements at the Visit</description>
        <time_frame>7 days after the onset of monotherapy</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Isoniazid, 600 mg</title>
            <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Early Bactericidal Activity (0-7)</title>
          <description>EBA (0-7): PCR, the mean of two measurements at the Visit</description>
          <population>FAS</population>
          <units>cell count per 1 mL of sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.044" spread="0.076"/>
                    <measurement group_id="O2" value="-0.004" spread="0.081"/>
                    <measurement group_id="O3" value="0.116" spread="0.186"/>
                    <measurement group_id="O4" value="-0.408" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Сmax) of PBTZ169</title>
        <description>Peak plasma concentration (Сmax) of PBTZ169 for multiple dosing</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA: the pharmacokinetic analysis population for multiple dosing comprised all patients participating in the PK study who had received at least one dose of the study drug PBTZ169, provided that data on study drug concentration (with at least one measurement above BLQ) was available.</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Сmax) of PBTZ169</title>
          <description>Peak plasma concentration (Сmax) of PBTZ169 for multiple dosing</description>
          <population>PKA: the pharmacokinetic analysis population for multiple dosing comprised all patients participating in the PK study who had received at least one dose of the study drug PBTZ169, provided that data on study drug concentration (with at least one measurement above BLQ) was available.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4714" spread="18.6498"/>
                    <measurement group_id="O2" value="122.0135" spread="96.3347"/>
                    <measurement group_id="O3" value="101.3818" spread="31.3830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Plasma Concentration (Сmin) of PBTZ169</title>
        <description>Minimal plasma concentration (Сmin) of PBTZ169: concentration measurement following single dosing</description>
        <time_frame>for single dosing , Day 1 (24 h after 1st dose of PBTZ169)</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Plasma Concentration (Сmin) of PBTZ169</title>
          <description>Minimal plasma concentration (Сmin) of PBTZ169: concentration measurement following single dosing</description>
          <population>PKA</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4985" spread="0.4475"/>
                    <measurement group_id="O2" value="0.2678" spread="0.3375"/>
                    <measurement group_id="O3" value="1.0275" spread="0.9101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Concentration (Ctrough) of PBTZ169</title>
        <description>Residual concentration (Ctrough) of PBTZ169, measured 24 hours after the first dose administration, prior to the last dose, and 24 hours after the last dose</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Concentration (Ctrough) of PBTZ169</title>
          <description>Residual concentration (Ctrough) of PBTZ169, measured 24 hours after the first dose administration, prior to the last dose, and 24 hours after the last dose</description>
          <population>PKA</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours after the first dose (Ctrough_SD24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7835" spread="0.6820"/>
                    <measurement group_id="O2" value="1.4116" spread="1.2712"/>
                    <measurement group_id="O3" value="1.8712" spread="0.9453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prior to the last dose (Ctrough_MD0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1610" spread="1.6332"/>
                    <measurement group_id="O2" value="4.9505" spread="1.4050"/>
                    <measurement group_id="O3" value="18.2674" spread="27.2441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours after the last dose (Ctrough_MD24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4207" spread="1.0145"/>
                    <measurement group_id="O2" value="2.9274" spread="1.4535"/>
                    <measurement group_id="O3" value="5.2710" spread="2.5201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Plasma Concentration (Сmin) of PBTZ169</title>
        <description>Minimal plasma concentration (Сmin) of PBTZ169: multiple dosing</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Plasma Concentration (Сmin) of PBTZ169</title>
          <description>Minimal plasma concentration (Сmin) of PBTZ169: multiple dosing</description>
          <population>PKA</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4207" spread="1.0145"/>
                    <measurement group_id="O2" value="3.3889" spread="2.0001"/>
                    <measurement group_id="O3" value="4.9322" spread="2.4003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax) of PBTZ169</title>
        <description>Time to reach maximum concentration (Tmax) of PBTZ169 after single oral administration in different doses</description>
        <time_frame>for single dosing , Day 1 (24 h after 1st dose of PBTZ169)</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) of PBTZ169</title>
          <description>Time to reach maximum concentration (Tmax) of PBTZ169 after single oral administration in different doses</description>
          <population>PKA</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.250" lower_limit="0.67" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.250" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="0.33" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax) of PBTZ169</title>
        <description>Time to reach maximum concentration (Tmax) of PBTZ169 after multiple oral administration in different doses</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) of PBTZ169</title>
          <description>Time to reach maximum concentration (Tmax) of PBTZ169 after multiple oral administration in different doses</description>
          <population>PKA</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="0.67" upper_limit="2.98"/>
                    <measurement group_id="O2" value="2.000" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="1.500" lower_limit="0.00" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24)</title>
        <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours]</description>
        <time_frame>Up to 24 hours after the first drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24)</title>
          <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours]</description>
          <population>PKA</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.604" spread="74.3008"/>
                    <measurement group_id="O2" value="120.954" spread="44.7920"/>
                    <measurement group_id="O3" value="237.153" spread="111.4025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (Сmax) of PBTZ169</title>
        <description>Peak plasma concentration (Сmax) of PBTZ169: concentration measurement following single dosing</description>
        <time_frame>for single dosing , Day 1 (24 h after 1st dose of PBTZ169)</time_frame>
        <population>PKA: the pharmacokinetic analysis population for multiple dosing comprised all patients participating in the PK study who had received at least one dose of the study drug PBTZ169, provided that data on study drug concentration (with at least one measurement above BLQ) was available.</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Сmax) of PBTZ169</title>
          <description>Peak plasma concentration (Сmax) of PBTZ169: concentration measurement following single dosing</description>
          <population>PKA: the pharmacokinetic analysis population for multiple dosing comprised all patients participating in the PK study who had received at least one dose of the study drug PBTZ169, provided that data on study drug concentration (with at least one measurement above BLQ) was available.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6543" spread="18.8506"/>
                    <measurement group_id="O2" value="35.5370" spread="23.4983"/>
                    <measurement group_id="O3" value="79.6684" spread="49.1865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24)</title>
        <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours] for the last dosing (Day 14)</description>
        <time_frame>Up to 24 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24)</title>
          <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours] for the last dosing (Day 14)</description>
          <population>PKA</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.293" spread="73.9862"/>
                    <measurement group_id="O2" value="349.308" spread="282.1627"/>
                    <measurement group_id="O3" value="502.895" spread="167.7201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC (0-t)</title>
        <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-last concentration above lower limit of quantification (LLoQ)]</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t)</title>
          <description>Area under the plasma concentration of PBTZ169 versus time curve in frames [0-last concentration above lower limit of quantification (LLoQ)]</description>
          <population>PKA</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.259" spread="73.9728"/>
                    <measurement group_id="O2" value="356.170" spread="282.0489"/>
                    <measurement group_id="O3" value="502.075" spread="168.5111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-∞) of PBTZ169</title>
        <description>Area under the plasma concentration versus time curve in frames [0-∞]</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞) of PBTZ169</title>
          <description>Area under the plasma concentration versus time curve in frames [0-∞]</description>
          <population>PKA</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.855" spread="87.0391"/>
                    <measurement group_id="O2" value="412.819" spread="299.2734"/>
                    <measurement group_id="O3" value="568.581" spread="189.4584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratios for the PK Parameters AUC(0 -24)</title>
        <description>Accumulation ratios for the PK parameter AUC(0 -24): AUC(0- 24,ss)/AUC(0 -24), Day 1, on the original scale</description>
        <time_frame>24 hours after the first and the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratios for the PK Parameters AUC(0 -24)</title>
          <description>Accumulation ratios for the PK parameter AUC(0 -24): AUC(0- 24,ss)/AUC(0 -24), Day 1, on the original scale</description>
          <population>PKA</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.81" upper_limit="2.76"/>
                    <measurement group_id="O2" value="2.35" lower_limit="1.28" upper_limit="4.34"/>
                    <measurement group_id="O3" value="2.74" lower_limit="1.58" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration (Css,av) of PBTZ169</title>
        <description>Average steady-state concentration in the dosing interval following multiple dosing was evaluated as the ratio AUC0 24/τ (τ = the dosing interval)</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration (Css,av) of PBTZ169</title>
          <description>Average steady-state concentration in the dosing interval following multiple dosing was evaluated as the ratio AUC0 24/τ (τ = the dosing interval)</description>
          <population>PKA</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="862.63" spread="606.973"/>
                    <measurement group_id="O2" value="793.27" spread="212.270"/>
                    <measurement group_id="O3" value="532.95" spread="325.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluctuations (%) in the Dosing Interval</title>
        <description>Fluctuations (%) in the dosing interval after multiple dosing ((Cmax - Cmin) × 100%/Css,av)</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Fluctuations (%) in the Dosing Interval</title>
          <description>Fluctuations (%) in the dosing interval after multiple dosing ((Cmax - Cmin) × 100%/Css,av)</description>
          <population>PKA</population>
          <units>% (ratio)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32955.25" spread="18636.037"/>
                    <measurement group_id="O2" value="24703.16" spread="19047.811"/>
                    <measurement group_id="O3" value="16253.19" spread="7977.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total (Plasma) Clearance (Clt) of PBTZ169</title>
        <description>Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.</description>
        <time_frame>24 hours after the first drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total (Plasma) Clearance (Clt) of PBTZ169</title>
          <description>Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.</description>
          <population>PKA</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3293.80" spread="3329.026"/>
                    <measurement group_id="O2" value="2375.06" spread="759.203"/>
                    <measurement group_id="O3" value="2935.49" spread="1382.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total (Plasma) Clearance (Clt) of PBTZ169</title>
        <description>Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.</description>
        <time_frame>24 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total (Plasma) Clearance (Clt) of PBTZ169</title>
          <description>Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.</description>
          <population>PKA</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1393.31" spread="606.676"/>
                    <measurement group_id="O2" value="1200.61" spread="899.707"/>
                    <measurement group_id="O3" value="1259.77" spread="519.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vd) of PBTZ169</title>
        <description>Distribution volume Vd for a dosing interval of 72 hours after the last dose</description>
        <time_frame>Up to 72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vd) of PBTZ169</title>
          <description>Distribution volume Vd for a dosing interval of 72 hours after the last dose</description>
          <population>PKA</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7206" spread="3.0828"/>
                    <measurement group_id="O2" value="14.5545" spread="11.7568"/>
                    <measurement group_id="O3" value="20.9540" spread="6.9883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Half-life Time (T1/2) of PBTZ169</title>
        <time_frame>24 hours after the fist drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Half-life Time (T1/2) of PBTZ169</title>
          <population>PKA</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.201" spread="4.6319"/>
                    <measurement group_id="O2" value="16.469" spread="9.5669"/>
                    <measurement group_id="O3" value="10.110" spread="2.1530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Half-life Time (T1/2) of PBTZ169</title>
        <time_frame>24 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Half-life Time (T1/2) of PBTZ169</title>
          <population>PKA</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.524" spread="4.0037"/>
                    <measurement group_id="O2" value="13.790" spread="2.3234"/>
                    <measurement group_id="O3" value="8.883" spread="2.5338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Constant (Kel) of PBTZ169</title>
        <description>Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve.</description>
        <time_frame>24 hours after the first drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Constant (Kel) of PBTZ169</title>
          <description>Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve.</description>
          <population>PKA</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0797" spread="0.0371"/>
                    <measurement group_id="O2" value="0.0524" spread="0.0250"/>
                    <measurement group_id="O3" value="0.0708" spread="0.0126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Constant (Kel) of PBTZ169</title>
        <description>Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve.</description>
        <time_frame>72 hours after the last drug administration</time_frame>
        <population>PKA</population>
        <group_list>
          <group group_id="O1">
            <title>PBTZ169, 160 mg</title>
            <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>PBTZ169, 320 mg</title>
            <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
          <group group_id="O3">
            <title>PBTZ169, 640 mg</title>
            <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Constant (Kel) of PBTZ169</title>
          <description>Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve.</description>
          <population>PKA</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0470" spread="0.0123"/>
                    <measurement group_id="O2" value="0.0515" spread="0.0098"/>
                    <measurement group_id="O3" value="0.0828" spread="0.0211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection and evaluation of safety data started at the Screening Visit (Day -10 to -1) after signing the informed consent form and was continued till the last visit of the patient within the study (Day 21+1)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PBTZ169, 160 mg</title>
          <description>2 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="E2">
          <title>PBTZ169, 320 mg</title>
          <description>4 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="E3">
          <title>PBTZ169, 640 mg</title>
          <description>8 capsules 80 mg of PBTZ169 once a day for 14 days
PBTZ169: Once a day for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Isoniazid, 600 mg</title>
          <description>2 tablets 300 mg of Isoniazid once a day for 14 days
Isoniazid: Once a day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Spontaneously opened tuberculous paraproctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Wandering atrial pacemaker</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Metabolic disorders found in ECG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>QTc elongation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>QTc(F) shortening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Repolarization disturbances in the V1 lead in ECG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Reduced (+)T amplitude in standard leads</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ESR over 2.5 x normal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreements between the Principal Investigators and the CRO restricts the PIs' rights to discuss or publish trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Viсtoria Shcherbakova</name_or_title>
      <organization>Nearmedic Plus</organization>
      <phone>+7 (495) 741 49 89 ext 3869</phone>
      <email>Viktoriya.Shcherbakova@nearmedic.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

